Th17 cells in neuromyelitis optica spectrum disorder: a review

References

• Matiello M, Jacob A, Wingerchuk DM, et al. Neuromyelitis optica. Curr Opin Neurol 2007;20(3):255–60. doi: 10.1097/WCO.0b013e32814f1c6b. PubMed PMID: 17495617.
   PubMed Web of Science ®Google Scholar
• Wingerchuk DM, Hogancamp WF, O'Brien PC, et al. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology 1999;53(5):1107–14. PubMed PMID: 10496275.
   PubMed Web of Science ®Google Scholar
• Rossi A, Ratelade J, Papadopoulos MC, et al. Consequences of NMO-IgG binding to aquaporin-4 in neuromyelitis optica. Proc Natl Acad Sci U S A 2012;109(24):E1511. author reply E1512. doi:10.1073/pnas.1203463109. PubMed PMID: 22589299.
   Google Scholar
• Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004;364(9451):2106–12. doi:10.1016/S0140-6736(04)17551-X. PubMed PMID: 15589308.
   PubMed Web of Science ®Google Scholar
• Gelfand EW. Intravenous immune globulin in autoimmune and inflammatory diseases. N Engl J Med 2012;367(21):2015–25. doi:10.1056/NEJMra1009433. PubMed PMID: 23171098.
   PubMed Web of Science ®Google Scholar
• Squatrito D, Colagrande S, Emmi L. Devic's syndrome and primary APS: a new immunological overlap. Lupus 2010;19(11):1337–9. doi:10.1177/0961203310368968. PubMed PMID: 20504834.
   PubMed Web of Science ®Google Scholar
• Jones MV, Huang H, Calabresi PA, et al. Pathogenic aquaporin-4 reactive T cells are sufficient to induce mouse model of neuromyelitis optica. Acta Neuropathol Commun 2015;3:28. doi:10.1186/s40478-015-0207-1. PubMed PMID: 25990016.
   PubMed Web of Science ®Google Scholar
• Wang HH, Dai YQ, Qiu W, et al. Interleukin-17-secreting T cells in neuromyelitis optica and multiple sclerosis during relapse. J Clin Neurosci 2011;18(10):1313–7. doi:10.1016/j.jocn.2011.01.031. PubMed PMID: 21795048.
   PubMed Web of Science ®Google Scholar
• Li Y, Wang H, Long Y, et al. Increased memory Th17 cells in patients with neuromyelitis optica and multiple sclerosis. J Neuroimmunol 2011;234(1–2):155–60. doi:10.1016/j.jneuroim.2011.03.009. PubMed PMID: 21489641.
   PubMed Web of Science ®Google Scholar
• Uzawa A, Mori M, Ito M, et al. Markedly increased CSF interleukin-6 levels in neuromyelitis optica, but not in multiple sclerosis. J Neurol 2009;256(12):2082–4. doi:10.1007/s00415-009-5274-4. PubMed PMID: 19655191.
   PubMed Web of Science ®Google Scholar
• Jarius S, Frederikson J, Waters P, et al. Frequency and prognostic impact of antibodies to aquaporin-4 in patients with optic neuritis. J Neurol Sci 2010;298(1–2):158–62. doi:10.1016/j.jns.2010.07.011. PubMed PMID: 20850793.
   PubMed Web of Science ®Google Scholar
• Kitley J, Woodhall M, Waters P, et al. Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype. Neurology 2012;79(12):1273–7. doi:10.1212/WNL.0b013e31826aac4e. PubMed PMID: 22914827.
   PubMed Web of Science ®Google Scholar
• Nishiyama S, Ito T, Misu T, et al. A case of NMO seropositive for aquaporin-4 antibody more than 10 years before onset. Neurology 2009;72(22):1960–1. doi: 10.1212/WNL.0b013e3181a82621. PubMed PMID: 19487655.
   PubMed Web of Science ®Google Scholar
• Matsushita T, Matsuoka T, Isobe N, et al. Association of the HLA-DPB1*0501 allele with anti-aquaporin-4 antibody positivity in Japanese patients with idiopathic central nervous system demyelinating disorders. Tissue Antigens 2009;73(2):171–6. doi: 10.1111/j.1399-0039.2008.01172.x. PubMed PMID: 19140826.
   PubMed Web of Science ®Google Scholar
• Lindsey JW, Meulmester KM, Brod SA, et al. Variable results after rituximab in neuromyelitis optica. J Neurol Sci 2012;317(1–2):103–5. doi: 10.1016/j.jns.2012.02.017. PubMed PMID: 22405926.
   PubMed Web of Science ®Google Scholar
• Bennett JL, Lam C, Kalluri SR, et al. Intrathecal pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica. Ann Neurol 2009;66(5):617–29. doi: 10.1002/ana.21802. PubMed PMID: 19938104.
   PubMed Web of Science ®Google Scholar
• Bradl M, Misu T, Takahashi T, et al. Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo. Ann Neurol 2009;66(5):630–43. doi: 10.1002/ana.21837. PubMed PMID: 19937948.
   PubMed Web of Science ®Google Scholar
• Lucchinetti CF, Mandler RN, McGavern D, et al. A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain 2002;125(Pt 7):1450–61. PubMed PMID: 12076996.
   PubMed Web of Science ®Google Scholar
• Linhares UC, Schiavoni PB, Barros PO, et al. The ex vivo production of IL-6 and IL-21 by CD4+ T cells is directly associated with neurological disability in neuromyelitis optica patients. J Clin Immunol 2013;33(1):179–89. doi: 10.1007/s10875-012-9780-2. PubMed PMID: 22948743.
   PubMed Web of Science ®Google Scholar
• Herges K, de Jong BA, Kolkowitz I, et al. Protective effect of an elastase inhibitor in a neuromyelitis optica-like disease driven by a peptide of myelin oligodendroglial glycoprotein. Mult Scler 2012;18(4):398–408. doi: 10.1177/1352458512440060. PubMed PMID: 22343184.
   PubMed Web of Science ®Google Scholar
• Barros PO, Cassano T, Hygino J, et al. Prediction of disease severity in neuromyelitis optica by the levels of IL-6 produced during remission phase. Clin Exp Immunol 2015;183(3):480–9. doi: 10.1111/cei.12733. PubMed PMID: 26472479.
   PubMed Web of Science ®Google Scholar
• Ishizu T, Osoegawa M, Mei FJ, et al. Intrathecal activation of the IL-17/IL-8 axis in opticospinal multiple sclerosis. Brain 2005;128(Pt 5):988–1002. doi: 10.1093/brain/awh453. PubMed PMID: 15743872.
   PubMed Web of Science ®Google Scholar
• Wu A, Zhong X, Wang H, et al. Cerebrospinal fluid IL-21 levels in neuromyelitis optica and multiple sclerosis. Can J Neurol Sci 2012;39(6):813–20. PubMed PMID: 23041403.
   PubMed Web of Science ®Google Scholar
• Varrin-Doyer M, Spencer CM, Schulze-Topphoff U, et al. Aquaporin 4-specific T cells in neuromyelitis optica exhibit a Th17 bias and recognize Clostridium ABC transporter. Ann Neurol 2012;72(1):53–64. doi: 10.1002/ana.23651. PubMed PMID: 22807325.
   PubMed Web of Science ®Google Scholar
• Axtell RC, Raman C, Steinman L. Interferon-beta exacerbates Th17-mediated inflammatory disease. Trends Immunol 2011;32(6):272–7. doi: 10.1016/j.it.2011.03.008. PubMed PMID: 21530402.
   PubMed Web of Science ®Google Scholar
• Axtell RC, Raman C. Janus-like effects of type I interferon in autoimmune diseases. Immunol Rev 2012;248(1):23–35. doi: 10.1111/j.1600-065X.2012.01131.x. PubMed PMID: 22725952.
   PubMed Web of Science ®Google Scholar
• Vaknin-Dembinsky A, Brill L, Orpaz N, et al. Preferential increase of B-cell activating factor in the cerebrospinal fluid of neuromyelitis optica in a white population. Mult Scler 2010;16(12):1453–7. doi: 10.1177/1352458510380416. PubMed PMID: 20935029.
   PubMed Web of Science ®Google Scholar
• Hsu HC, Yang P, Wang J, et al. Interleukin 17-producing T helper cells and interleukin 17 orchestrate autoreactive germinal center development in autoimmune BXD2 mice. Nat Immunol 2008;9(2):166–75. doi: 10.1038/ni1552. PubMed PMID: 18157131.
   PubMed Web of Science ®Google Scholar
• A Vaknin-Dembinsky LB, I Kassis PP. T-cell responses to distinct AQP4 peptides in patients with neuromyelitis optica (NMO). Mult Scler Related Disord 2016;6:28–36.
   PubMed Web of Science ®Google Scholar
• Argyriou AA, Makris N. Neuromyelitis optica: a distinct demyelinating disease of the central nervous system. Acta Neurol Scand 2008;118(4):209–17. doi: 10.1111/j.1600-0404.2008.01002.x. PubMed PMID: 18336627.
   PubMed Web of Science ®Google Scholar
• Kira J. Neuromyelitis optica and opticospinal multiple sclerosis: mechanisms and pathogenesis. Pathophysiology 2011;18(1):69–79. doi: 10.1016/j.pathophys.2010.04.008. PubMed PMID: 20494560
   PubMedGoogle Scholar
• Roemer SF, Parisi JE, Lennon VA, et al. Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain 2007;130(Pt 5):1194–205. doi: 10.1093/brain/awl371. PubMed PMID: 17282996.
   PubMed Web of Science ®Google Scholar
• Jarius S, Paul F, Franciotta D, et al. Mechanisms of disease: aquaporin-4 antibodies in neuromyelitis optica. Nat Clin Pract Neurol 2008;4(4):202–14. doi: 10.1038/ncpneuro0764. PubMed PMID: 18334978.
   PubMedGoogle Scholar
• Jarius S, Wildemann B. AQP4 antibodies in neuromyelitis optica: diagnostic and pathogenetic relevance. Nat Rev Neurol 2010;6(7):383–92. doi: 10.1038/nrneurol.2010.72. PubMed PMID: 20639914.
   PubMed Web of Science ®Google Scholar
• Saadoun S, Waters P, Bell BA, et al. Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice. Brain 2010;133(Pt 2):349–61. doi: 10.1093/brain/awp309. PubMed PMID: 20047900.
   PubMed Web of Science ®Google Scholar
• Schneider P, MacKay F, Steiner V, et al. BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med 1999;189(11):1747–56. PubMed PMID: 10359578.
   PubMed Web of Science ®Google Scholar
• Okada K, Matsushita T, Kira J, et al. B-cell activating factor of the TNF family is upregulated in neuromyelitis optica. Neurology 2010;74(2):177–8. doi: 10.1212/WNL.0b013e3181c919ee. PubMed PMID: 20065253.
   PubMed Web of Science ®Google Scholar
• Jarius S, Wildemann B. AQP4 antibodies in neuromyelitis optica: diagnostic and pathogenetic relevance. Nat Rev Neurol 2010;6(7):383–92. doi: 10.1038/nrneurol.2010.72. PubMed PMID: 20639914.
   PubMed Web of Science ®Google Scholar
• Wang H, Wang K, Zhong X, et al. Cerebrospinal fluid BAFF and APRIL levels in neuromyelitis optica and multiple sclerosis patients during relapse. J Clin Immunol 2012;32(5):1007–11. doi: 10.1007/s10875-012-9709-9. PubMed PMID: 22644841.
   PubMed Web of Science ®Google Scholar
• Becker-Merok A, Nikolaisen C, Nossent HC. B-lymphocyte activating factor in systemic lupus erythematosus and rheumatoid arthritis in relation to autoantibody levels, disease measures and time. Lupus 2006;15(9):570–6. PubMed PMID: 17080911.
   PubMed Web of Science ®Google Scholar
• Groom JR, Fletcher CA, Walters SN, et al. BAFF and MyD88 signals promote a lupuslike disease independent of T cells. J Exp Med 2007;204(8):1959–71. doi: 10.1084/jem.20062567. PubMed PMID: 17664289.
   PubMed Web of Science ®Google Scholar
• Pers JO, Daridon C, Devauchelle V, et al. BAFF overexpression is associated with autoantibody production in autoimmune diseases. Ann N Y Acad Sci 2005;1050:34–9. doi: 10.1196/annals.1313.004. PubMed PMID: 16014518.
   PubMed Web of Science ®Google Scholar
• Groom J, Kalled SL, Cutler AH, et al. Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjogren's syndrome. J Clin Invest 2002;109(1):59–68. doi: 10.1172/JCI14121. PubMed PMID: 11781351.
   PubMed Web of Science ®Google Scholar
• Quan C, ZhangBao J, Lu J, et al. The immune balance between memory and regulatory B cells in NMO and the changes of the balance after methylprednisolone or rituximab therapy. J Neuroimmunol 2015;282:45–53. doi: 10.1016/j.jneuroim.2015.03.016. PubMed PMID: 25903728.
   PubMed Web of Science ®Google Scholar
• Cree BA, Lamb S, Morgan K, et al. An open label study of the effects of rituximab in neuromyelitis optica. Neurology 2005;64(7):1270–2. doi: 10.1212/01.WNL.0000159399.81861.D5. PubMed PMID: 15824362.
   PubMed Web of Science ®Google Scholar
• Jacob A, Weinshenker BG, Violich I, et al. Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch Neurol 2008;65(11):1443–8. doi: 10.1001/archneur.65.11.noc80069. PubMed PMID: 18779415.
   PubMed Web of Science ®Google Scholar
• Bedi GS, Brown AD, Delgado SR, et al. Impact of rituximab on relapse rate and disability in neuromyelitis optica. Mult Scler 2011;17(10):1225–30. doi: 10.1177/1352458511404586. PubMed PMID: 21622594.
   PubMed Web of Science ®Google Scholar
• Kim SH, Kim W, Li XF, et al. Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years. Arch Neurol 2011;68(11):1412–20. doi: 10.1001/archneurol.2011.154. PubMed PMID: 21747007.
   PubMedGoogle Scholar
• Greenberg BM, Graves D, Remington G, et al. Rituximab dosing and monitoring strategies in neuromyelitis optica patients: creating strategies for therapeutic success. Mult Scler 2012;18(7):1022–6. doi: 10.1177/1352458511432896. PubMed PMID: 22261118.
   PubMed Web of Science ®Google Scholar
• Korn T, Bettelli E, Oukka M, et al. IL-17 and Th17 cells. Annu Rev Immunol 2009;27:485–517. doi: 10.1146/annurev.immunol.021908.132710. PubMed PMID: 19132915.
   PubMed Web of Science ®Google Scholar
• Song X, Gao H, Qian Y. Th17 differentiation and their pro-inflammation function. Adv Exp Med Biol 2014;841:99–151. doi: 10.1007/978-94-017-9487-9_5. PubMed PMID: 25261206.
   PubMed Web of Science ®Google Scholar
• Afzali B, Lombardi G, Lechler RI, et al. The role of T helper 17 (Th17) and regulatory T cells (Treg) in human organ transplantation and autoimmune disease. Clin Exp Immunol 2007;148(1):32–46. doi: 10.1111/j.1365-2249.2007.03356.x. PubMed PMID: 17328715.
   PubMed Web of Science ®Google Scholar
• Wong CK, Lit LC, Tam LS, et al. Hyperproduction of IL-23 and IL-17 in patients with systemic lupus erythematosus: implications for Th17-mediated inflammation in auto-immunity. Clin Immunol 2008;127(3):385–93. doi: 10.1016/j.clim.2008.01.019. PubMed PMID: 18373953.
   PubMed Web of Science ®Google Scholar
• Pernis AB. Th17 cells in rheumatoid arthritis and systemic lupus erythematosus. J Intern Med 2009;265(6):644–52. doi: 10.1111/j.1365-2796.2009.02099.x. PubMed PMID: 19493058.
   PubMed Web of Science ®Google Scholar
• Lowes MA, Kikuchi T, Fuentes-Duculan J, et al. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J Invest Dermatol 2008;128(5):1207–11. doi: 10.1038/sj.jid.5701213. PubMed PMID: 18200064.
   PubMed Web of Science ®Google Scholar
• Yokote H, Yagi Y, Watanabe Y, et al. Serum amyloid A level is increased in neuromyelitis optica and atypical multiple sclerosis with smaller T2 lesion volume in brain MRI. J Neuroimmunol 2013;259(1–2):92–5. doi: 10.1016/j.jneuroim.2013.03.004. PubMed PMID: 23566403.
   PubMed Web of Science ®Google Scholar
• Qu N, Xu M, Mizoguchi I, et al. Pivotal roles of T-helper 17-related cytokines, IL-17, IL-22, and IL-23, in inflammatory diseases. Clin Dev Immunol 2013;2013:968549. doi: 10.1155/2013/968549. PubMed PMID: 23956763.
   PubMed Web of Science ®Google Scholar
• Icoz S, Tuzun E, Kurtuncu M, et al. Enhanced IL-6 production in aquaporin-4 antibody positive neuromyelitis optica patients. Int J Neurosci 2010;120(1):71–5. doi: 10.3109/00207450903428970. PubMed PMID: 20128675.
   PubMed Web of Science ®Google Scholar
• Correale J, Fiol M. Activation of humoral immunity and eosinophils in neuromyelitis optica. Neurology 2004;63(12):2363–70. PubMed PMID: 15623701.
   PubMed Web of Science ®Google Scholar
• Uzawa A, Mori M, Sawai S, et al. Cerebrospinal fluid interleukin-6 and glial fibrillary acidic protein levels are increased during initial neuromyelitis optica attacks. Clin Chim Acta 2013;421:181–3. doi: 10.1016/j.cca.2013.03.020. PubMed PMID: 23535508.
   PubMed Web of Science ®Google Scholar
• Kaplin AI, Deshpande DM, Scott E, et al. IL-6 induces regionally selective spinal cord injury in patients with the neuroinflammatory disorder transverse myelitis. J Clin Invest 2005;115(10):2731–41. doi: 10.1172/JCI25141. PubMed PMID: 16184194.
   PubMed Web of Science ®Google Scholar
• Zhang H, Bennett JL, Verkman AS. Ex vivo spinal cord slice model of neuromyelitis optica reveals novel immunopathogenic mechanisms. Ann Neurol 2011;70(6):943– 54. doi: 10.1002/ana.22551. PubMed PMID: 22069219.
   PubMed Web of Science ®Google Scholar
• Frei K, Malipiero UV, Leist TP, et al. On the cellular source and function of interleukin 6 produced in the central nervous system in viral diseases. Eur J Immunol 1989;19(4):689–94. doi: 10.1002/eji.1830190418. PubMed PMID: 2543584.
   PubMed Web of Science ®Google Scholar
• Gottschall PE, Tatsuno I, Arimura A. Regulation of interleukin-6 (IL-6) secretion in primary cultured rat astrocytes: synergism of interleukin-1 (IL-1) and pituitary adenylate cyclase activating polypeptide (PACAP). Brain Res 1994;637(1–2):197–203. PubMed PMID: 7910101.
   PubMed Web of Science ®Google Scholar
• Li XZ, Bai LM, Yang YP, et al. Effects of IL-6 secreted from astrocytes on the survival of dopaminergic neurons in lipopolysaccharide-induced inflammation. Neurosci Res 2009;65(3):252–8. doi: 10.1016/j.neures.2009.07.007. PubMed PMID: 19647022.
   PubMed Web of Science ®Google Scholar
• Mitsdoerffer M, Lee Y, Jager A, et al. Proinflammatory T helper type 17 cells are effective B-cell helpers. Proc Natl Acad Sci U S A 2010;107(32):14292–7. doi: 10.1073/pnas.1009234107. PubMed PMID: 20660725.
   PubMed Web of Science ®Google Scholar
• Takahashi T, Fujihara K, Nakashima I, et al. Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre. Brain 2007;130(Pt 5):1235–43. doi: 10.1093/brain/awm062. PubMed PMID: 17449477.
   PubMed Web of Science ®Google Scholar
• Uzawa A, Mori M, Arai K, et al. Cytokine and chemokine profiles in neuromyelitis optica: significance of interleukin-6. Mult Scler 2010;16(12):1443–52. doi: 10.1177/1352458510379247. PubMed PMID: 20739337.
   PubMed Web of Science ®Google Scholar
• Chihara N, Aranami T, Sato W, et al. Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica. Proc Natl Acad Sci U S A 2011;108(9):3701–6. doi: 10.1073/pnas.1017385108. PubMed PMID: 21321193.
   PubMed Web of Science ®Google Scholar
• Tanaka M, Matsushita T, Tateishi T, et al. Distinct CSF cytokine/chemokine profiles in atopic myelitis and other causes of myelitis. Neurology 2008;71(13):974–81. doi: 10.1212/01.wnl.0000326589.57128.c3. PubMed PMID: 18809833.
   PubMed Web of Science ®Google Scholar
• Jacob A, Matiello M, Wingerchuk DM, et al. Neuromyelitis optica: changing concepts. J Neuroimmunol 2007;187(1–2):126–38. doi: 10.1016/j.jneuroim.2007.04.009. PubMed PMID: 17512987.
   PubMed Web of Science ®Google Scholar
• Tzartos JS, Friese MA, Craner MJ, et al. Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. Am J Pathol 2008;172(1):146–55. doi: 10.2353/ajpath.2008.070690. PubMed PMID: 18156204.
   PubMed Web of Science ®Google Scholar
• Matsushita T, Tateishi T, Isobe N, et al. Characteristic cerebrospinal fluid cytokine/chemokine profiles in neuromyelitis optica, relapsing remitting or primary progressive multiple sclerosis. PLoS One 2013;8(4):e61835. doi: 10.1371/journal.pone.0061835. PubMed PMID: 23637915.
   PubMed Web of Science ®Google Scholar
• Wang H, Zhong X, Wang K, et al. Interleukin 17 gene polymorphism is associated with anti-aquaporin 4 antibody-positive neuromyelitis optica in the Southern Han Chinese – a case control study. J Neurol Sci 2012;314(1–2):26–8. doi: 10.1016/j.jns.2011.11.005. PubMed PMID: 22118860.
   PubMed Web of Science ®Google Scholar
• Barros PO, Linhares UC, Teixeira B, et al. High in vitro immune reactivity to Escherichia coli in neuromyelitis optica patients is correlated with both neurological disabilities and elevated plasma lipopolysaccharide levels. Hum Immunol 2013;74(9):1080–7. doi: 10.1016/j.humimm.2013.06.016. PubMed PMID: 23777933.
   PubMed Web of Science ®Google Scholar
• Liu SM, King C. IL-21-producing Th cells in immunity and autoimmunity. J Immunol 2013;191(7):3501–6. doi: 10.4049/jimmunol.1301454. PubMed PMID: 24058193.
   PubMed Web of Science ®Google Scholar
• Spolski R, Leonard WJ. IL-21 and T follicular helper cells. Int Immunol 2010;22(1):7–12. doi: 10.1093/intimm/dxp112. PubMed PMID: 19933709.
   PubMed Web of Science ®Google Scholar
• Lee Y, Mitsdoerffer M, Xiao S, et al. IL-21R signaling is critical for induction of spontaneous experimental autoimmune encephalomyelitis. J Clin Invest 2015;125(11):4011–20. doi: 10.1172/JCI75933. PubMed PMID: 26413871.
   PubMed Web of Science ®Google Scholar
• Okamoto T, Ogawa M, Lin Y, et al. Treatment of neuromyelitis optica: current debate. Ther Adv Neurol Disord 2008;1(1):5–12. doi: 10.1177/1756285608093978. PubMed PMID: 21180560.
   PubMedGoogle Scholar
• Yanagawa K, Kawachi I, Toyoshima Y, et al. Pathologic and immunologic profiles of a limited form of neuromyelitis optica with myelitis. Neurology 2009;73(20):1628–37. doi: 10.1212/WNL.0b013e3181c1deb9. PubMed PMID: 19917985.
   PubMed Web of Science ®Google Scholar
• Kroenke MA, Carlson TJ, Andjelkovic AV, et al. IL-12- and IL-23-modulated T cells induce distinct types of EAE based on histology, CNS chemokine profile, and response to cytokine inhibition. J Exp Med 2008;205(7):1535–41. doi: 10.1084/jem.20080159. PubMed PMID: 18573909.
   PubMed Web of Science ®Google Scholar
• Stromnes IM, Cerretti LM, Liggitt D, et al. Differential regulation of central nervous system autoimmunity by T(H)1 and T(H)17 cells. Nat Med 2008;14(3):337–42. doi: 10.1038/nm1715. PubMed PMID: 18278054.
   PubMed Web of Science ®Google Scholar
• Wojkowska DW, Szpakowski P, Ksiazek-Winiarek D, et al. Interactions between neutrophils, Th17 cells, and chemokines during the initiation of experimental model of multiple sclerosis. Mediators Inflamm 2014;2014:590409. doi: 10.1155/2014/590409. PubMed PMID: 24692851.
   PubMed Web of Science ®Google Scholar
• Pierson E, Simmons SB, Castelli L, et al. Mechanisms regulating regional localization of inflammation during CNS autoimmunity. Immunol Rev 2012;248(1):205–15. doi: 10.1111/j.1600-065X.2012.01126.x. PubMed PMID: 22725963.
   PubMed Web of Science ®Google Scholar
• Goverman J. Autoimmune T cell responses in the central nervous system. Nat Rev Immunol 2009;9(6):393–407. doi: 10.1038/nri2550. PubMed PMID: 19444307.
   PubMed Web of Science ®Google Scholar
• Rothhammer V, Heink S, Petermann F, et al. Th17 lymphocytes traffic to the central nervous system independently of α4 integrin expression during EAE. J Exp Med 2011;208(12):2465–76. doi: 10.1084/jem.20110434. PubMed PMID: 22025301.
   PubMed Web of Science ®Google Scholar
• Knier B, Rothhammer V, Heink S, et al. Neutralizing IL-17 protects the optic nerve from autoimmune pathology and prevents retinal nerve fiber layer atrophy during experimental autoimmune encephalomyelitis. J Autoimmun 2015;56:34–44. doi: 10.1016/j.jaut.2014.09.003. PubMed PMID: 25282335.
   PubMed Web of Science ®Google Scholar
• Vincent T, Saikali P, Cayrol R, et al. Functional consequences of neuromyelitis optica-IgG astrocyte interactions on blood-brain barrier permeability and granulocyte recruitment. J Immunol 2008;181(8):5730–7. PubMed PMID: 18832732.
   PubMed Web of Science ®Google Scholar
• Tasaki A, Shimizu F, Sano Y, et al. Autocrine MMP-2/9 secretion increases the BBB permeability in neuromyelitis optica. J Neurol Neurosurg Psychiatry 2014;85(4):419–30. doi: 10.1136/jnnp-2013-305907. PubMed PMID: 24259591.
   PubMed Web of Science ®Google Scholar
• Shimizu F, Nishihara H, Sano Y, et al. Markedly increased IP-10 production by blood-brain barrier in neuromyelitis optica. PLoS One 2015;10(3):e0122000. doi: 10.1371/journal.pone.0122000. PubMed PMID: 25811465.
   PubMed Web of Science ®Google Scholar
• Amiry-Moghaddam M, Ottersen OP. The molecular basis of water transport in the brain. Nat Rev Neurosci 2003;4(12):991–1001. doi: 10.1038/nrn1252. PubMed PMID: 14682361.
   PubMed Web of Science ®Google Scholar
• Nielsen S, Nagelhus EA, Amiry-Moghaddam M, et al. Specialized membrane domains for water transport in glial cells: high-resolution immunogold cytochemistry of aquaporin-4 in rat brain. J Neurosci 1997;17(1):171–80. PubMed PMID: 8987746.
   PubMed Web of Science ®Google Scholar
• Morita R, Schmitt N, Bentebibel SE, et al. Human blood CXCR5(+)CD4(+) T cells are counterparts of T follicular cells and contain specific subsets that differentially support antibody secretion. Immunity 2011;34(1):108–21. doi: 10.1016/j.immuni.2010.12.012. PubMed PMID: 21215658.
   PubMed Web of Science ®Google Scholar
• Mitsdoerffer M, Kuchroo V, Korn T. Immunology of neuromyelitis optica: a T cell-B cell collaboration. Ann N Y Acad Sci 2013;1283:57–66. doi: 10.1111/nyas.12118. PubMed PMID: 23617588.
   PubMed Web of Science ®Google Scholar
• Argyriou AA, Makris N. Neuromyelitis optica: a distinct demyelinating disease of the central nervous system. Acta Neurol Scand 2008;118(4):209–17. doi: 10.1111/j.1600-0404.2008.01002.x. PubMed PMID: 18336627.
   PubMed Web of Science ®Google Scholar
• Zhou X, Xia Z, Lan Q, et al. BAFF promotes Th17 cells and aggravates experimental autoimmune encephalomyelitis. PLoS One 2011;6(8):e23629. doi: 10.1371/journal.pone.0023629. PubMed PMID: 21897850.
   Google Scholar
• Eilertsen GO, Van Ghelue M, Strand H, et al. Increased levels of BAFF in patients with systemic lupus erythematosus are associated with acute-phase reactants, independent of BAFF genetics: a case-control study. Rheumatology (Oxford) 2011;50(12):2197–205. doi: 10.1093/rheumatology/ker282. PubMed PMID: 21984763.
   PubMed Web of Science ®Google Scholar
• Collongues N, de Seze J. Current and future treatment approaches for neuromyelitis optica. Ther Adv Neurol Disord 2011;4(2):111–21. doi: 10.1177/1756285611398939. PubMed PMID: 21694808.
   PubMedGoogle Scholar
• Qiu W, Kermode AG, Li R, et al. Azathioprine plus corticosteroid treatment in Chinese patients with neuromyelitis optica. J Clin Neurosci 2015;22(7):1178–82. doi: 10.1016/j.jocn.2015.01.028. PubMed PMID: 26006157.
   PubMed Web of Science ®Google Scholar
• Weinstock-Guttman B, Ramanathan M, Lincoff N, et al. Study of mitoxantrone for the treatment of recurrent neuromyelitis optica (Devic disease). Arch Neurol 2006;63(7):957–63. doi: 10.1001/archneur.63.7.957. PubMed PMID: 16831964.
   PubMedGoogle Scholar
• Miyamoto K, Kusunoki S. Intermittent plasmapheresis prevents recurrence in neuromyelitis optica. Ther Apher Dial 2009;13(6):505–8. doi: 10.1111/j.1744-9987.2009.00780.x. PubMed PMID: 19954473.
   PubMed Web of Science ®Google Scholar
• Jacob A, Matiello M, Weinshenker BG, et al. Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients. Arch Neurol 2009;66(9):1128–33. doi: 10.1001/archneurol.2009.175. PubMed PMID: 19752302.
   PubMedGoogle Scholar
• Uzawa A, Mori M, Hayakawa S, et al. Different responses to interferon beta-1b treatment in patients with neuromyelitis optica and multiple sclerosis. Eur J Neurol 2010;17(5):672–6. doi: 10.1111/j.1468-1331.2009.02897.x. PubMed PMID: 20039942.
   PubMed Web of Science ®Google Scholar
• Palace J, Leite MI, Nairne A, et al. Interferon beta treatment in neuromyelitis optica: increase in relapses and aquaporin 4 antibody titers. Arch Neurol 2010;67(8):1016–7. doi: 10.1001/archneurol.2010.188. PubMed PMID: 20697055.
   PubMedGoogle Scholar
• Uzawa A, Mori M, Hayakawa S, et al. Different responses to interferon beta-1b treatment in patients with neuromyelitis optica and multiple sclerosis. Eur J Neurol 2010;17(5):672–6. doi: 10.1111/j.1468-1331.2009.02897.x. PubMed PMID: 20039942.
   PubMed Web of Science ®Google Scholar
• Kieseier BC, Stuve O, Dehmel T, et al. Disease amelioration with tocilizumab in a treatment-resistant patient with neuromyelitis optica: implication for cellular immune responses. JAMA Neurol 2013;70(3):390–3. doi: 10.1001/jamaneurol.2013.668. PubMed PMID: 23599943.
   PubMed Web of Science ®Google Scholar
• Ayzenberg I, Kleiter I, Schroder A, et al. Interleukin 6 receptor blockade in patients with neuromyelitis optica nonresponsive to anti-CD20 therapy. JAMA Neurol 2013;70(3):394–7. doi: 10.1001/jamaneurol.2013.1246. PubMed PMID: 23358868.
   PubMed Web of Science ®Google Scholar
• Araki M, Aranami T, Matsuoka T, et al. Clinical improvement in a patient with neuromyelitis optica following therapy with the anti-IL-6 receptor monoclonal antibody tocilizumab. Mod Rheumatol 2013;23(4):827–31. doi: 10.1007/s10165-012-0715-9. PubMed PMID: 22782533.
   PubMed Web of Science ®Google Scholar
• Wingerchuk DM. Neuromyelitis optica spectrum disorders. Continuum (Minneap Minn) 2010;16(5 Multiple Sclerosis):105–21. doi: 10.1212/01.CON.0000389937.69413.15. PubMed PMID: 22810601.
   PubMedGoogle Scholar
• Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 2015;85(2):177–89. doi: 10.1212/WNL.0000000000001729. PubMed PMID: 26092914.
   PubMed Web of Science ®Google Scholar
• Vitaliti G, Tabatabaie O, Matin N, et al. The usefulness of immunotherapy in pediatric neurodegenerative disorders: a systematic review of literature data. Hum Vaccin Immunother 2015;11(12):2749–63. doi: 10.1080/21645515.2015.1061161. PubMed PMID: 26266339.
   PubMed Web of Science ®Google Scholar
• Shalaby SM, Sabbah NA, Saber T, et al. Adipose-derived mesenchymal stem cells modulate the immune response in chronic experimental autoimmune encephalomyelitis model. IUBMB Life 2016;68(2):106–15. doi: 10.1002/iub.1469. PubMed PMID: 26757144.
   PubMed Web of Science ®Google Scholar
• Piao Z, Kim HJ, Choi JY, et al. Effect of FOXP3 polymorphism on the clinical outcomes after allogeneic hematopoietic stem cell transplantation in pediatric acute leukemia patients. Int Immunopharmacol 2015;31:132–9. doi: 10.1016/j.intimp.2015.12.022. PubMed PMID: 26735609.
   PubMed Web of Science ®Google Scholar
• Oliveira MC, Labopin M, Henes J, et al. Does ex vivo CD34+ positive selection influence outcome after autologous hematopoietic stem cell transplantation in systemic sclerosis patients. Bone Marrow Transplant 2015. doi: 10.1038/bmt.2015.299. PubMed PMID: 26642332.
   Web of Science ®Google Scholar
• Ra JC, Kang SK, Shin IS, et al. Stem cell treatment for patients with autoimmune disease by systemic infusion of culture-expanded autologous adipose tissue derived mesenchymal stem cells. J Transl Med 2011;9:181. doi: 10.1186/1479-5876-9-181. PubMed PMID: 22017805.
   PubMed Web of Science ®Google Scholar
• Lu Z, Ye D, Qian L, et al. Human umbilical cord mesenchymal stem cell therapy on neuromyelitis optica. Curr Neurovasc Res 2012;9(4):250–5. PubMed PMID: 22873728.
   PubMed Web of Science ®Google Scholar
• Najar M, Raicevic G, Boufker HI, et al. Adipose-tissue-derived and Wharton's jelly-derived mesenchymal stromal cells suppress lymphocyte responses by secreting leukemia inhibitory factor. Tissue Eng Part A 2010;16(11):3537–46. doi: 10.1089/ten.TEA.2010.0159. PubMed PMID: 20597819.
   PubMed Web of Science ®Google Scholar
• Nicola NA, Babon JJ. Leukemia inhibitory factor (LIF). Cytokine Growth Factor Rev 2015;26(5):533–44. doi: 10.1016/j.cytogfr.2015.07.001. PubMed PMID: 26187859.
   PubMed Web of Science ®Google Scholar
• Buck D, Förschler A, Lapa C, et al. 18F-FDG PET detects inflammatory infiltrates in spinal cord experimental autoimmune encephalomyelitis lesions. J Nucl Med 2012;53(8):1269–76. doi: 10.2967/jnumed.111.102608. PubMed PMID: 22738927.
   PubMed Web of Science ®Google Scholar